Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 24 03:36PM ET
55.92
Dollar change
-0.49
Percentage change
-0.87
%
Index- P/E- EPS (ttm)-1.97 Insider Own5.21% Shs Outstand84.88M Perf Week0.65%
Market Cap4.75B Forward P/E- EPS next Y-4.06 Insider Trans-3.49% Shs Float80.46M Perf Month-21.33%
Income-153.61M PEG- EPS next Q-2.00 Inst Own65.75% Short Float18.34% Perf Quarter-11.25%
Sales371.21M P/S12.79 EPS this Y-203.03% Inst Trans-0.04% Short Ratio8.42 Perf Half Y44.80%
Book/sh23.52 P/B2.38 EPS next Y30.93% ROA-6.87% Short Interest14.76M Perf Year7.52%
Cash/sh19.95 P/C2.80 EPS next 5Y- ROE-8.17% 52W Range37.55 - 91.10 Perf YTD-10.67%
Dividend Est.- P/FCF- EPS past 5Y10.83% ROI-7.29% 52W High-38.62% Beta1.78
Dividend TTM- Quick Ratio17.54 Sales past 5Y33402.13% Gross Margin65.88% 52W Low48.92% ATR (14)2.81
Dividend Ex-Date- Current Ratio17.54 EPS Y/Y TTM76.72% Oper. Margin-53.64% RSI (14)29.24 Volatility5.32% 3.79%
Employees407 Debt/Eq0.13 Sales Y/Y TTM30885.48% Profit Margin-41.38% Recom2.21 Target Price87.61
Option/ShortYes / Yes LT Debt/Eq0.12 EPS Q/Q177.83% Payout- Rel Volume0.40 Prev Close56.41
Sales Surprise42.76% EPS Surprise1559.13% Sales Q/Q3353333.33% EarningsFeb 21 BMO Avg Volume1.75M Price55.92
SMA20-10.18% SMA50-22.54% SMA200-6.15% Trades Volume660,842 Change-0.87%
Date Action Analyst Rating Change Price Target Change
Feb-15-24Initiated Wolfe Research Peer Perform
Dec-11-23Downgrade TD Cowen Market Perform → Underperform $30
Oct-17-23Downgrade Cantor Fitzgerald Overweight → Neutral
Sep-27-23Initiated Mizuho Buy $82
Aug-17-23Upgrade Citigroup Neutral → Buy
May-30-23Initiated William Blair Outperform $75
Apr-13-23Initiated Cantor Fitzgerald Overweight $72
Mar-21-23Initiated Bernstein Mkt Perform $44
Mar-17-23Initiated Bryan Garnier Buy $70
Mar-07-23Initiated Robert W. Baird Neutral $46
Apr-22-24 06:00PM
04:30PM
12:49PM
Apr-19-24 10:31PM
06:56AM
09:00AM Loading…
Apr-17-24 09:00AM
Apr-16-24 06:00PM
Apr-13-24 08:47AM
Apr-11-24 01:10PM
Apr-10-24 01:46PM
Apr-09-24 06:00PM
10:00AM
Apr-05-24 05:03AM
Apr-04-24 06:15PM
Apr-03-24 08:00AM
08:00AM Loading…
Apr-01-24 08:00AM
Mar-30-24 06:50AM
Mar-28-24 08:39AM
Mar-27-24 04:50AM
Mar-25-24 06:15PM
Mar-24-24 10:08AM
Mar-23-24 06:45AM
Mar-22-24 11:30AM
Mar-21-24 04:19PM
Mar-20-24 01:49PM
Mar-19-24 06:15PM
12:07AM
Mar-17-24 08:50AM
Mar-16-24 08:45AM
Mar-14-24 08:15AM
02:25PM Loading…
Mar-13-24 02:25PM
08:30AM
Mar-06-24 02:45PM
Mar-05-24 06:53PM
Mar-04-24 11:02AM
08:48AM
Feb-29-24 05:32PM
06:31AM
05:50AM
Feb-27-24 12:00PM
Feb-26-24 08:50AM
06:45AM
Feb-23-24 10:01AM
Feb-22-24 07:37AM
04:00AM
Feb-21-24 04:32PM
10:15AM
07:30AM
Feb-20-24 05:02AM
Feb-19-24 04:08PM
01:45AM
Feb-16-24 02:19PM
07:31AM
Feb-15-24 08:30AM
Feb-14-24 08:15AM
Feb-13-24 01:22PM
10:00AM
08:30AM
02:30AM
Feb-10-24 05:09PM
Feb-09-24 06:00PM
Feb-08-24 02:59AM
Feb-07-24 10:00AM
09:09AM
Feb-05-24 08:00AM
Feb-04-24 02:35PM
Feb-02-24 06:00PM
Feb-01-24 09:10PM
Jan-31-24 12:28PM
Jan-30-24 05:10AM
05:02AM
Jan-28-24 05:10AM
Jan-25-24 06:15PM
08:32AM
Jan-24-24 09:45AM
Jan-23-24 09:30AM
Jan-22-24 09:12AM
05:05AM
Jan-21-24 09:37AM
08:00AM
Jan-20-24 06:50AM
Jan-19-24 06:15PM
Jan-16-24 04:08PM
04:01PM
08:15AM
Jan-15-24 04:56PM
06:30AM
05:19AM
Jan-14-24 01:30PM
05:10AM
Jan-13-24 06:05AM
05:20AM
Jan-10-24 06:00AM
Jan-09-24 06:15PM
Jan-08-24 09:17AM
07:00AM
05:00AM
Jan-06-24 05:00AM
Jan-04-24 05:00AM
Jan-03-24 12:17PM
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kulkarni SamarthChief Executive OfficerApr 15 '24Option Exercise19.1219,582374,408227,704Apr 17 05:45 PM
Kulkarni SamarthChief Executive OfficerApr 15 '24Sale59.9119,5821,173,232208,122Apr 17 05:45 PM
Kulkarni SamarthChief Executive OfficerMar 15 '24Option Exercise19.1220,000382,400228,122Mar 18 05:45 PM
Kulkarni SamarthChief Executive OfficerMar 15 '24Sale72.4820,0001,449,628208,122Mar 18 05:45 PM
Prasad RajuChief Financial OfficerMar 15 '24Sale72.693,524256,1606,476Mar 18 05:45 PM
Kulkarni SamarthChief Executive OfficerMar 12 '24Sale74.444,583341,159208,122Mar 12 05:45 PM
KASINGER JAMES R.General Counsel and SecretaryMar 12 '24Sale74.441,14685,30861,174Mar 12 05:45 PM
Kulkarni SamarthChief Executive OfficerMar 11 '24Sale78.269,802767,105203,705Mar 12 05:45 PM
KASINGER JAMES R.General Counsel and SecretaryMar 11 '24Sale78.262,801219,20660,070Mar 12 05:45 PM
Kulkarni SamarthChief Executive OfficerFeb 20 '24Sale79.676,370507,498194,257Feb 21 05:45 PM
KASINGER JAMES R.General Counsel and SecretaryFeb 20 '24Sale79.671,913152,40957,371Feb 21 05:45 PM
Kulkarni SamarthChief Executive OfficerFeb 15 '24Option Exercise19.1220,000382,400207,377Feb 16 05:45 PM
Kulkarni SamarthChief Executive OfficerFeb 15 '24Sale80.3620,0001,607,177187,377Feb 16 05:45 PM
Kulkarni SamarthChief Executive OfficerJan 29 '24Option Exercise19.1250,000956,000237,377Jan 31 05:45 PM
Kulkarni SamarthChief Executive OfficerJan 29 '24Sale60.5150,0003,025,573187,377Jan 31 05:45 PM
Kulkarni SamarthChief Executive OfficerJan 16 '24Option Exercise19.1220,000382,400207,377Jan 18 05:45 PM
Kulkarni SamarthChief Executive OfficerJan 16 '24Sale62.5020,0001,250,058187,377Jan 18 05:45 PM
Kulkarni SamarthChief Executive OfficerMay 30 '23Option Exercise19.1225,000478,000412,377Jun 01 05:44 PM
Kulkarni SamarthChief Executive OfficerMay 30 '23Sale64.8825,0001,621,894387,377Jun 01 05:44 PM
Kulkarni SamarthChief Executive OfficerApr 25 '23Option Exercise19.1225,000478,000412,377Apr 27 05:37 PM
Kulkarni SamarthChief Executive OfficerApr 25 '23Sale50.6725,0001,266,638387,377Apr 27 05:37 PM